The Experts below are selected from a list of 93093 Experts worldwide ranked by ideXlab platform
Peter Dietrich - One of the best experts on this subject based on the ideXlab platform.
-
Patients with Immune-Mediated Inflammatory Diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.
Nature communications, 2020Co-Authors: David Simon, Koray Tascilar, Gerhard Krönke, Arnd Kleyer, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Peter DietrichAbstract:Immune-Mediated Inflammatory Diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of Inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.
-
Patients with Immune-Mediated Inflammatory Diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection
2020Co-Authors: David Simon, Koray Tascilar, Arnd Kleyer, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Gerhard Krönk, Peter DietrichAbstract:Abstract Immune-Mediated Inflammatory Diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of Inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observed a significantly reduced incidence of SARS-CoV-2 infection in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.Authors David Simon and Koray Tascilar contributed equally to this work. Authors Markus F. Neurath and Georg Schett share senior authorship.
Hans Prenen - One of the best experts on this subject based on the ideXlab platform.
-
Cancer risk in Immune-Mediated Inflammatory Diseases: IMID and Cancer Risk.
Molecular Cancer, 2013Co-Authors: Rudi Beyaert, Gert Van Assche, Manuelle Viguier, Lieve Brochez, Guy Jerusalem, Jean-christophe Renauld, Veronique Cocquyt, Jean-pascal Machiels, Laurent Beaugerie, Hans PrenenAbstract:: Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but Inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.This article reviews current literature on the role of inflammation in cancer and the cancer risk in Immune-Mediated Inflammatory Diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.Overall cancer incidence and mortality risk are similar to the general population in Inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.This review provides clinicians with a solid background to help them in making decisions about treatment of Immune-Mediated Diseases in patients with a tumor history.
-
Cancer risk in Immune-Mediated Inflammatory Diseases (IMID)
Molecular cancer, 2013Co-Authors: Rudi Beyaert, Gert Van Assche, Manuelle Viguier, Lieve Brochez, Guy Jerusalem, Jean-christophe Renauld, Veronique Cocquyt, Jean-pascal Machiels, Laurent Beaugerie, Hans PrenenAbstract:Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but Inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors. This article reviews current literature on the role of inflammation in cancer and the cancer risk in Immune-Mediated Inflammatory Diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors. Overall cancer incidence and mortality risk are similar to the general population in Inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce. This review provides clinicians with a solid background to help them in making decisions about treatment of Immune-Mediated Diseases in patients with a tumor history. This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.
Eugeni Domènech - One of the best experts on this subject based on the ideXlab platform.
-
Immune-Mediated Inflammatory Diseases differently affect IGRAs’ accuracy for latent tuberculosis infection diagnosis in clinical practice
PloS one, 2017Co-Authors: Irene Latorre, Sonia Mínguez, José Manuel Carrascosa, Juan E. Naves, Raquel Villar-hernández, Beatriz Muriel, Cristina Prat, Esther García-garcía, Irma Casas, Eugeni DomènechAbstract:Background. Clinical accuracy of IGRAs remains unclear on patients with Immune-Mediated Inflammatory Diseases (IMIDs). Here, we assess the impact of immunosuppressants and IMIDs on QuantiFERON-TB Gold In-Tube (QFN-G-IT) and T-SPOT.TB accuracy. Methods. Patients with IMIDs who required latent tuberculosis infection (LTBI) screening were enrolled and classified into: (i) 50 patients with Inflammatory rheumatic Diseases, (ii) 50 patients with psoriasis and (iii) 30 patients with Crohn's disease. A total of 44 healthy individuals without immunosuppression were also included as controls. Tuberculin skin test (TST), T-SPOT.TB and QFN-G-IT assays were performed. IGRAs were performed following manufacturer's instructions. Results. Immunosuppressant's intake was more frequent on patients with Crohn's disease and psoriasis. Positive IGRAs and TST results were reduced in Crohn's disease patients, whereas rate of indeterminate T-SPOT.TB results was increased in this group with respect to the other IMIDs analysed and controls. When IFN-γ response was studied, the levels of this cytokine after mitogen stimulation were significantly lower in Crohn's and Inflammatoryrheumatic Diseases than in psoriasis. Interestingly, psoriatic patients were the only ones not receiving corticosteroids. Furthermore, a negative correlation was observed between the IFN-γ secreted after mitogen stimulation and corticosteroids dose. Conclusions. IMIDs seem to negatively affect the clinical accuracy of IGRAs, being Crohn's disease patients the most affected individuals due to their concomitant drug-profile and impaired immune response.
-
Cardiovascular disease in Immune-Mediated Inflammatory Diseases: A cross-sectional analysis of 6 cohorts.
Medicine, 2017Co-Authors: Benjamín Fernández-gutiérrez, Juan D. Cañete, Jesús Tornero, Antonio Fernández-nebro, Pedro P. Perrotti, Javier P. Gisbert, Eugeni Domènech, Carlos Ferrándiz, Valle García-sánchez, Julián PanésAbstract:AbstractTo analyze in several Immune-Mediated Inflammatory Diseases (IMIDs) the influence of demographic and clinical-related variables on the prevalence of cardiovascular disease (CVD), and compare their standardized prevalences.Cross-sectional study, including consecutive patients diagnosed with r
-
Urine metabolome profiling of Immune-Mediated Inflammatory Diseases
BMC medicine, 2016Co-Authors: Arnald Alonso, Juan D. Cañete, Jesús Tornero, Antonio Fernández-nebro, Antonio Julià, Javier P. Gisbert, Eugeni Domènech, Carlos Ferrándiz, Maria Vinaixa, Pilar NosAbstract:Immune-Mediated Inflammatory Diseases (IMIDs) are a group of complex and prevalent Diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn’s disease, and ulcerative colitis. Using nuclear magnetic resonance, we analyzed the urine metabolome in a discovery cohort of 1210 patients and 100 controls. Within each IMID, two patient subgroups were recruited representing extreme disease activity (very high vs. very low). Metabolite association analysis with disease diagnosis and disease activity was performed using multivariate linear regression in order to control for the effects of clinical, epidemiological, or technical variability. After multiple test correction, the most significant metabolite biomarkers were validated in an independent cohort of 1200 patients and 200 controls. In the discovery cohort, we identified 28 significant associations between urine metabolite levels and disease diagnosis and three significant metabolite associations with disease activity (PFDR
-
SAT0122 Common and Specific Risk Factors for Cardiovascular Disease Among 6 Immune-Mediated Inflammatory Diseases: A Cross-Sectional Analysis
Annals of the Rheumatic Diseases, 2015Co-Authors: Luis Rodriguez-rodriguez, Juan D. Cañete, Jesús Tornero, Antonio Fernández-nebro, Pedro P. Perrotti, Javier P. Gisbert, Eugeni Domènech, Carlos Ferrándiz, Adrià Aterido, M. Lόpez-lasantaAbstract:Background Immune mediated and Inflammatory Diseases (IMIDs) such a rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis (Ps), and psoriatic arthritis (PsA), are associated with higher rates of cardiovascular (CV) morbidity and mortality, mostly due to accelerated atherosclerosis. Classic CV risk factors do not fully account for the gap observed in the prevalence and incidence of CV disease, when compared to that of the general population. Objectives To analyze the influence of different demographic and clinical variables in the prevalence of CV disease in subjects affected with RA, PsA, Ps, SLE, or Inflammatory bowel disease. Additionally, we compared the adjusted prevalence of CV disease among these conditions. Methods Subjects included in this cross-sectional study were collected as part of the Immune-Mediated Inflammatory Disease Consortium (IMIDC) between 2007 and 2010. Demographic, disease and cardiovascular related clinical data was collected using a standard protocol of questionnaires, after a clinical interview with close questions and review of medical records. Bivariate and multivariate logistic and mixed-effects logistic regression models were performed for each condition, and the overall IMIDC, respectively. Standardize prevalence (SP) for each IMID was calculated using marginal analysis. Results 9951 patients were included. When analyzed separately, traditional CV risk factors had a different contribution to CV disease in each IMID. Overall, when analyzed all subjects, older age at study, longer elapsed time from IMID diagnosis to study, presence of traditional CV risk factors (arterial hypertension, type2 diabetes mellitus, dyslipidemia, obesity) and male gender were independently associated with a higher CV disease risk. After adjusting by demographic and traditional CV risk factors, SLE exhibited the highest SP, followed by RA and Ps/Crohn9s disease. Conclusions Cardiovascular disease is related to Immune-Mediated Inflammatory Diseases. A different impact is shown dependent of particular disease directly affecting the burden of disease. Acknowledgements We would like to thank all the patients and physicians for their collaboration. Disclosure of Interest None declared
Tiago Torres - One of the best experts on this subject based on the ideXlab platform.
-
Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases.
Current drug safety, 2017Co-Authors: Rui Pedro Gomes Pereira, Paula Lago, Raquel Faria, Tiago TorresAbstract:Abstract Infectious and malignant events are responsible for morbidity and mortality in patients with Immune-Mediated Inflammatory Diseases (IMIDs). Anti-tumor necrosis factor (Anti-TNF) agents appear to have an impact, however the individual effect of these agents in the different conditions is still unclear. The goal of this study is to estimate the Incidence Rates (IR) of infections and malignancies in patients treated with anti-TNFs across different IMIDs, as well as potential risk factors. IR/100 patient-years were evaluated in adult patients treated for any IMID with an anti-TNF between January 2000 and December 2014. Predictors were tested with bivariate and multivariate statistical analysis. The IR/100 patient-years of serious infections was 4.02 (95% CI 3.20-5.04) with significant differences across IMIDs and anti-TNF agents. The most frequent site of serious infection was the gastrointestinal system. Five cases [IR of 0.28 (95% CI 0.12-0.66) /100 patient-years] of Tuberculosis were diagnosed, exclusively in patients treated with monoclonal antibodies. Three (60%) of those were extrapulmonary. The IR/100 patient-years of malignancy was 1.75 (95% CI 1.24-2-47). Methotrexate, in this study, was associated with a decrease in malignant risk. There is significant variability in the IR of infections across indications and agents. Thus, physicians should be thoughtful when generalizing data from literature regarding the use of an anti-TNF agent in a specific IMID. Further studies are necessary to clear aspects regarding the safety of individual anti-TNF biologics and to clarify their impact in the different IMIDs.
-
Safety of Anti‐TNF Therapies in Immune‐Mediated Inflammatory Diseases: Focus on Infections and Malignancy
Drug development research, 2015Co-Authors: Rui Pedro Gomes Pereira, Paula Lago, Raquel Faria, Tiago TorresAbstract:Preclinical Research The efficacy of anti-TNF agents in the treatment of multiple Immune-Mediated Inflammatory Diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and Inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient.
Hsin-hua Chen - One of the best experts on this subject based on the ideXlab platform.
-
Factors associated with sepsis risk in Immune-Mediated Inflammatory Diseases receiving tumor necrosis factor inhibitors: a nationwide study.
Therapeutic advances in musculoskeletal disease, 2020Co-Authors: Wen-cheng Chao, Chen-yu Wang, Bo-chueh Hsu, Ching-heng Lin, Wen-nan Huang, Yi-hsing Chen, Hsin-hua ChenAbstract:Background:Risk factors for sepsis have not been assessed in patients receiving tumor necrosis factor-alpha inhibitors (TNFi) for Immune-Mediated Inflammatory Diseases (IMIDs) who are vulnerable to...
